cyanobacterial neurotoxin bmaa als alzheimer's disease pubmed ncbi abstract objective aim study screen quantify neurotoxic amino acid beta-n-methylamino-l-alanine bmaa cohort autopsy specimens alzheimer's disease ad amyotrophic lateral sclerosis als huntington's disease hd non-neurological controls bmaa produced cyanobacteria found variety freshwater marine terrestrial habitats possibility geographically broad human exposure bmaa suggested discovery bmaa brain tissues chamorro patients als/parkinsonism dementia complex guam recently ad patients north america observations warranted independent study bmaa exposures guam ecosystem methods postmortem brain specimens neuropathologically confirmed cases num als num ad num hd patients num age-matched non-neurological controls bmaa quantified validated fluorescent hplc method previously detect bmaa patients guam tandem mass spectrometric ms analysis carried confirm identification bmaa neurological specimens results detected quantified bmaa neuroproteins postmortem brain tissue patients united states died sporadic ad als hd incidental detections observed num regions analyzed controls concentrations bmaa reported previously chamarro als parkinsonism dementia complex patients demonstrated twofold range disease regional brain area comparisons presence bmaa patients confirmed triple quadrupole liquid chromatography/mass spectrometry/mass spectrometry conclusions occurrence bmaa north american als ad patients suggests possibility gene/environment interaction bmaa triggering neurodegeneration vulnerable individuals num authors journal compilation num blackwell munksgaard 
